Stock data
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS) reported revenue of US$7.83M and net income of -US$64.92M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$7.83M | — | -US$76.38M | -US$64.92M | — |
| 2024 | US$18.72M | — | -US$141.93M | -US$132.06M | — |
| 2023 | US$31.25M | — | -US$97.36M | -US$88.48M | — |
| 2022 | US$29.75M | — | -US$89.85M | -US$86.91M | — |
| 2021 | US$6.76M | — | -US$89.72M | -US$90.86M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$1.63M | -US$21.50M | — |
| 2026-03-31 | US$2.00M | -US$19.82M | — |
| 2025-12-31 | US$1.29M | -US$19.80M | — |
| 2025-09-30 | US$3.30M | -US$14.61M | — |
| 2025-06-30 | US$1.78M | -US$15.43M | — |
| 2025-03-31 | US$1.46M | -US$15.09M | — |
| 2024-12-31 | US$9.21M | -US$96.55M | — |
| 2024-09-30 | US$4.35M | -US$7.59M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.